Fluoroquinolone resistance in Mycobacterium tuberculosis: The effect of duration and timing of fluoroquinolone exposure

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 4, 2009, Pages 365-370

  Devasia, Rose A ^a   Blackman, Amondrea ^a   Gebretsadik, Tebeb ^a   Griffin, Marie ^a   Shintani, Ayumi ^a   May, Carolyn ^a   Smith, Teresa ^b   Hooper, Nancy ^c   Maruri, Fernanda ^a   Warkentin, Jon ^b   Mitchel, Ed ^a   Sterling, Timothy R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TENNESSEE DEPARTMENT OF HEALTH   (United States)

^c Maryland State Laboratory   (United States)

Author keywords

Antibacterial; Drug resistance; Mycobacteria

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; UNITED STATES;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 68849086908     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200901-0146OC     Document Type: Article

References (19)

1. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
2. Hoffner SE, Gezelius L, Olsson-Liljequist B. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997;40:885-888.
3. Berlin OG, Young LS, Bruckner DA. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. J Antimicrob Chemother 1987;19:611-615.
4. Narayanan P. Shortening short course chemotherapy: a randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc 2002;49:27-38.
5. Chaisson RE, Conde M, Efron A, Loredo C. A randomized placebo-controlled trial of moxifloxacin vs. Ethambutol in the initial phase of tuberculosis therapy in Brazil. Interscience Conference of Antimicrobial Agents and Chemotherapy. Sept. 17-20, 2007, Chicago, IL. Abstract L-736-A.
6. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-138.
7. Linder J, Huang E, Steinman M, Gonzales R, Stafford R. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005;118:259-268.
8. Mandell L, Wunderink R, Anzueto A, Bartlett J, Campbell G, Dean N, Dowell S, File T Jr, Musher D, Niederman M, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.
9. Gaba PD, Haley C, Griffin MR, Mitchel E, Warkentin J, Holt E, Baggett P, Sterling TR. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007;167:2317-2322.
10. Ginsburg AS, Woolwine SC, Hooper N, Benjamin WH Jr, Bishai WR, Dorman SE, Sterling TR. The rapid development of fluoroquinolone resistance in M. Tuberculosis. N Engl J Med 2003;349:1977-1978.
11. Bozeman L, Burman W, Metchok B, Welch L, Weiner M, Tuberculosis Trials Consortium. Fluoroquinolone susceptibility among mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2002;40:386-391.
12. Ginsburg A, Hoope N, Parrish N, Dooley K, Dorman S, Booth J, Diener-West M, Merz W, Bishai W, Sterling T. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003;37:1448-1452.
13. Umubyeyi A, Rigouts L, Shamputa I. Limited fluoroquinolone resistance among mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother 2007;59:1031-1033.
14. Park I, Hong S, Oh Y, Lim C, Lee S, Lew W. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007;11:319-323.
15. Devasia R, Griffin M, Blackman A, May S, Holt E, Smith T, Warkentin J, Mitchel E. Trends in fluoroquinolone resistance and exposure in newly diagnosed tuberculosis: 2002-2006 [abstract]. Am J Respir Crit Care Med 2008;177:A19.
16. Clinical Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. CLSI document M24-A [ISBN 1-56238-500-3] Vol. 23. Wayne, PA: The Institute; 2003.
17. Cowan LS, Diem L, Monson T, Wand P, Temporado D, Oemig TV, Crawford JT. Evaluation of a two-step approach for large-scale, prospective genotyping of mycobacterium tuberculosis isolates in the United States. J Clin Microbiol 2005;43:688-695.
18. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, Hsueh PR, Yang PC. Fluoroquinolone resistance in mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007;59:860-865.
19. Centers for Disease Control and Prevention. Trends in tuberculosis. MMWR Morb Mortal Wkly Rep 2007;57:245-250.